Literature DB >> 31227648

Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.

Elad Neeman1, Gillian Gresham2, Navasard Ovasapians3, Andrew Hendifar2, Richard Tuli2, Robert Figlin2, Arvind Shinde4.   

Abstract

BACKGROUND: The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scale is commonly used by physicians and nurses in oncology, as it correlates with cancer morbidity, mortality, and complications from chemotherapy and can help direct clinical decisions and prognostication. This retrospective cohort study aimed to identify whether ECOG-PS scores rated by oncologist versus nurses differ in their ability to predict clinical outcomes.
MATERIALS AND METHODS: Over 19 months, 32 oncologists and 41 chemotherapy nurses from a single academic comprehensive cancer center independently scored ECOG-PS (range: 0-5) for a random sample of 311 patients with cancer receiving chemotherapy. Logistic regression models were fit to evaluate the ability of nurse and physician ECOG-PS scores, as well as the nurse-physician ECOG-PS score difference (nurse minus physician), to predict the occurrence of chemotherapy toxicity (CTCAE v4, grade ≥3) and hospitalizations within 1 month from ECOG-PS ratings, as well as 6-month mortality or hospice referrals.
RESULTS: Physician/nurse ECOG-PS agreement was 71% (Cohen's κ = 0.486, p < .0001). Nurse ECOG-PS scores had stronger odds ratio for 6-month mortality or hospice (odds ratio [OR], 3.29, p < .0001) than physician ECOG-PS scores (OR, 2.71, p = .001). Furthermore, ECOG-PS ratings by nurses, but not physicians, correlated with 1-month chemotherapy toxicity (OR, 1.44, p = .021) and 1-month hospitalizations (OR, 1.57, p = .041). Nurse-physician disagreement, but only when physicians gave "healthier" (lower) ratings, was also associated with worse outcomes (chemotherapy toxicity OR = 1.51, p = .045; 1-month hospitalization OR, 1.86, p = .037; 6-month mortality or hospice OR, 2.99, p < .0001).
CONCLUSION: Nurse ECOG-PS ratings seem more predictive of important outcomes than those of physicians, and physician-nurse disagreement in ECOG-PS ratings predicts worse outcomes; scoring by nurses may result in additional clinical benefit. IMPLICATIONS FOR PRACTICE: Nurse-rated Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores, compared with those rated by oncologists, better predicted hospitalizations and severe chemotherapy toxicity within 1 month from ECOG-PS assessment, as well as mortality or hospice referrals within 6 months. Physician-nurse disagreement in ECOG-PS scoring was associated with worse hospitalization, chemotherapy toxicity, and mortality and hospice referral rates. Rating performance statuses of patients with cancer by nurses instead or in addition to oncologists can result in additional clinical benefits, such as improved prognostication, as well as better informed clinical decision making regarding whether or not to administer chemotherapy, the need for additional supportive care, and goals of care discussions. © AlphaMed Press 2019.

Entities:  

Keywords:  Cancer survivors; Karnofsky Performance Status; Nursing assessment; Oncologists; Retrospective studies; Treatment outcome

Year:  2019        PMID: 31227648      PMCID: PMC6975959          DOI: 10.1634/theoncologist.2018-0882

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  21 in total

Review 1.  The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review.

Authors:  Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch
Journal:  Support Care Cancer       Date:  2015-08-28       Impact factor: 3.603

2.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

Authors:  Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag
Journal:  JAMA       Date:  2017-07-11       Impact factor: 56.272

3.  Longitudinal patient-reported performance status assessment in the cancer clinic is feasible and prognostic.

Authors:  Sang-Yeon Suh; Thomas W Leblanc; Rebecca A Shelby; Gregory P Samsa; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2011-11       Impact factor: 3.840

4.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

5.  Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.

Authors:  C K Lee; M R Stockler; A S Coates; V Gebski; S J Lord; R J Simes
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

6.  Health care providers underestimate symptom intensities of cancer patients: a multicenter European study.

Authors:  Eivor A Laugsand; Mirjam A G Sprangers; Kristin Bjordal; Frank Skorpen; Stein Kaasa; Pål Klepstad
Journal:  Health Qual Life Outcomes       Date:  2010-09-21       Impact factor: 3.186

Review 7.  Predicting life expectancy in patients with advanced incurable cancer: a review.

Authors:  Monica Krishnan; Jennifer S Temel; Alexi A Wright; Rachelle Bernacki; Kathy Selvaggi; Tracy Balboni
Journal:  J Support Oncol       Date:  2013-06

8.  Extent and determinants of error in physicians' prognoses in terminally ill patients: prospective cohort study.

Authors:  N A Christakis; E B Lamont
Journal:  West J Med       Date:  2000-05

9.  Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

Authors:  Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses.

Authors:  K C Sneeuw; N K Aaronson; M A Sprangers; S B Detmar; L D Wever; J H Schornagel
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  9 in total

1.  Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.

Authors:  Xiaojuan Lu; Junyan Wan; Huaqiu Shi
Journal:  Oncol Lett       Date:  2022-06-17       Impact factor: 3.111

2.  Evaluation of an inflammation-based score for identification of appropriate patients for comprehensive genomic profiling.

Authors:  Naomi Hayashi; Ippei Fukada; Akihiro Ohmoto; Masumi Yamazaki; Xiaofei Wang; Mari Hosonaga; Shunji Takahashi
Journal:  Discov Oncol       Date:  2022-10-19

Review 3.  Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Antonella Cammarota; Antonio D'Alessio; Tiziana Pressiani; Lorenza Rimassa; Nicola Personeni
Journal:  Drugs Aging       Date:  2021-06-21       Impact factor: 3.923

4.  Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods.

Authors:  Lei Peng; Chunxiao Du; Chunyang Meng; Jinze Li; Chengyu You; Xianhui Li; Pan Zhao; Dehong Cao; Yunxiang Li
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

5.  Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.

Authors:  Jun Zhu; Chunyan Song; Zhong Zheng; Lingfang Xia; Yanqiong Chen; Guihao Ke; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-11-02       Impact factor: 6.244

6.  Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients.

Authors:  Flavio Milana; Simone Famularo; Antonio Luberto; Lorenza Rimassa; Marta Scorsetti; Tiziana Comito; Tiziana Pressiani; Ciro Franzese; Dario Poretti; Luca Di Tommaso; Nicola Personeni; Marcello Rodari; Vittorio Pedicini; Matteo Donadon; Guido Torzilli
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

7.  Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.

Authors:  Wenhui Wang; Fenqiang Li; Peiying Gan; Baohua Li; Shuangxi Li
Journal:  Front Surg       Date:  2022-09-02

8.  Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.

Authors:  Qiufen Guo; Yawen Sun; Enqi Kong; Linli Rao; Jinlong Chen; Qian Wu; Tingting Zhang; Naifu Liu; Mingjiang Li; Li Sun
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

9.  Limitations and usefulness of biopsy techniques for the diagnosis of metastatic bone and soft tissue tumors.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Naohiro Oka; Masao Akagi
Journal:  Ann Med Surg (Lond)       Date:  2021-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.